企業プロフィール
Dyne Therapeutics 株価・ニュース・カタリスト
- ティッカー:
- DYN
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
26.10 USD (+0.46%)
終値
最終更新: 2026年8月21日
2.85B USD
時価総額
株価変動の要因
The latest company update was “Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)”. DYN changed 0.46% and closed at $26.10 on Aug 21, 2026, indicating a relatively limited closing-price reaction to this company update.
企業概要
Oligonucleotide Therapeutics
Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue.
Duchenne Muscular Dystrophy
Z-rostudirsen is designed for patients with Duchenne muscular dystrophy amenable to exon 51 skipping. The candidate has completed the registrational portion of the DELIVER program, and Dyne is preparing it for regulatory submission and commercialization.
Myotonic Dystrophy
Z-basivarsen targets toxic DMPK RNA in myotonic dystrophy type 1. It is being evaluated in the Phase 1/2 ACHIEVE study and the global confirmatory Phase 3 HARMONIA trial.
今後のカタリスト
- BLA submission for z-rostudirsen in the second quarter of 2026.
- Completion of enrollment in the registrational ACHIEVE expansion cohort for z-basivarsen in the second quarter of 2026.
- Potential U.S. launch of z-rostudirsen in the first quarter of 2027, subject to approval.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。